Xerna TME Panel

Products & Services

Information

The Xerna TME Panel is a novel biomarker panel for therapies targeting the tumor microenvironment (TME), such as immune checkpoint inhibitors (ICIs) and anti-angiogenic agents. Using RNA-sequencing and machine learning, the Xerna TME Panel classifies solid tumor samples into four subtypes based on the dominant biology of the TME. Each subtype represents a phenotype with a distinct therapeutic hypothesis and probability of response to treatment.
GenialisGenialis is the RNA biomarker company. We are creating a world where healthcare delivers the best possible outcomes for patients, their families and communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data.

Log in